Skip to content

Analysis of the Genotype/Phenotype Relationship in the Fuchs' Corneal Endothelial Dystrophy in France

Analysis of the Genotype/Phenotype Relationship in the Fuchs' Corneal Endothelial Dystrophy in France. The French Fuchs' Follow-up Study (Phase 2), F3S2

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05742321
Acronym
F3S2
Enrollment
500
Registered
2023-02-23
Start date
2024-08-08
Completion date
2026-06-01
Last updated
2024-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corneal Dystrophies

Keywords

Corneal Dystrophies, Corneal Endothelial Dystrophy, Fuchs' Corneal Endothelial Dystrophy, FECD

Brief summary

The pathophysiology of the most common corneal endothelial dystrophies (Fuchs' Corneal Endothelial Dystrophy, FECD) is beginning to be dismembered. There is a significant heterogeneity in the clinical forms and the investigators have just highlighted a great diversity of histological forms that seem to define distinct groups.

Detailed description

The most frequent genetic abnormalities have been published since 10 years and can now be easily searched. This study is going to analyze the relationships between clinical, histological and genetic forms in a large population to better understand how histological abnormalities are formed.

Interventions

GENETICGenotyping

Genotyping will measure the triple nucleotide repeat in the TCF4 gene and search for other known mutations in other genes Blood sample will be performed (genetic analyses).

DIAGNOSTIC_TESTHistology

Histology will be performed on flat mounted Descemet membrane obtained after Descemetorhexis

Collection of data of examination for diagnosis of the Fuchs Endothelial Corneal Dystrophy (FECD) including slit lamp results will be performed.

Sponsors

Kyoto University, Graduate School of Medicine
CollaboratorOTHER
Centre Hospitalier Universitaire de Saint Etienne
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* affiliated with or entitled to a social security scheme * Consent form to participate in the study signed * with an FECD certified by slit lamp examination * requiring an endothelial keratoplasty

Exclusion criteria

\- Patients under guardianship or curators

Design outcomes

Primary

MeasureTime frameDescription
Number of CTG triplet repetitions in the intron of the Transcription Factor 4 (TCF4) geneAt inclusionPolymerase Chain Reaction (PCR) will be performed from DNA (blood sample)

Secondary

MeasureTime frameDescription
ETDRS scale (international standardized Early Treatment Diabetic Retinopathy Study scale)At inclusionETDRS (Early Treatment Diabetic Retinopathy Study) scale will be allowed to measure visual acuity uses an eye chart with 5 letters per line. The scores range from 0 (no letters read correctly) to 100 (all letters read correctly).
Corneal thickness in Optical Coherence Tomography (OCT)At inclusionCorneal thickness measured by OCT in micrometers
Diameter of the dilated pupil (mm)At inclusionMeasured by contact or non-contact biometry
Thickness of the lens (mm)At inclusionMeasured by contact or non-contact biometry
Refraction with the auto-refractor tonometryAt inclusionAnalysis refraction with the auto-refractor tonometry non-contact air.
Endothelial cell density measurement (cells/mm2)Immediately after surgery of corneal transplantationEndothelial cell density (cells/mm2) in the center and in the 4 standardized cardinal positions high low nasal temporal.
Crystalline analysisImmediately after surgery of corneal transplantationCrystalline : clear lens, cataract, intraocular implant, aphakic
Family cases of Fuchs' Corneal Endothelial DystrophyAt inclusionFamily cases: absent/probable/advanced
Frequency of the mutation rs613872 in the intron of the Transcription Factor 4 (TCF4) gene.At inclusionPCR reactions will be performed from DNA (blood sample)
Depth of the anterior chamber (mm)At inclusionMeasured by contact or non-contact biometry

Countries

France

Contacts

Primary ContactGILLES THURET, MD-PhD
gilles.thuret@univ-st-etienne.fr(0)477127793
Backup ContactPHILIPPE GAIN, MD-PhD
philippe.gain@chu-st-etienne.fr0477127793

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026